ロード中...
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
BACKGROUND: HSP90 inhibition leads to proteosomal degradation of activated KIT and has in vitro activity against gastrointestinal stromal tumors (GIST). BIIB021 is an oral non-ansamycin HSP90 inhibitor. We carried out a phase II study of BIIB021 in patients with GIST refractory to imatinib and sunit...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2013
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4023320/ https://ncbi.nlm.nih.gov/pubmed/22898035 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds275 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|